Valbiotis announced that it has submitted the three clinical protocols for TOTUM?854, indicated in the reduction of blood pressure, to the competent authorities and presents its comprehensive clinical development plan, as announced at the annual meeting of the European Society of Hypertension and of the International Society of Hypertension in April 2021. TOTUM?854 is the second plant-based active substance from the Valbiotis product portfolio to enter Phase II/III clinical trials and will address an unmet medical demand for non-drug prevention of arterial hypertension. The TOTUM?854 clinical development program includes three clinical studies, whose results will be required in Europe and the United States for health claim applications in the reduction of blood pressure, which is a risk factor for cardiovascular disease. The clinical protocols for the three studies have been filed with the competent authorities. The INSIGHT international, multicenter, randomized, placebo-controlled Phase II/III clinical study will be conducted in a population of 400 volunteers with mild to moderate blood pressure elevation (systolic blood pressure between 130 mmHg and 159 mmHg and diastolic pressure <100 mmHg). It will include two groups: a TOTUM?854 group with a dose of 3.7 g/day and a placebo group. Its main objective will be to reduce systolic blood pressure in the TOTUM?854 group after 3 months of supplementation versus the placebo group. 24-hour ambulatory blood pressure measurements will also be taken as a secondary study endpoint. The end of recruitment is expected at the first semester of 2023.